There's moderate evidence of benefit in spasticity disorders and patients with MS. There's moderate evidence in chronic pain. There's weak evidence in anxiety, as well as sleep disorders. In educating people on prescribing, we have to be concerned that there are some red flags where you can see real challenges. Those are patients who have schizophrenia and bipolar disorder.
Part of the education that's required is to be able to bring that information out. Huge credit should be given to the Ontario Medical Association. Last October, they retained our research institute and we created the fundamentals of cannabis, module one, and a second one on pharmacokinetics and dynamics. They were distributed to the 36,000 doctors in Ontario. It's that kind of information that needs to be disseminated. Developing these education modules was funded by the OMA.
I think we're making very good progress, as has been reflected. We now have probably one in four physicians prescribing it. My only point is this: Are they prescribing it appropriately? That's the challenge that we need to address.